Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06201234
Title Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)
Acronym ELEMENT
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors German Breast Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU

Additional content available in CKB BOOST